Meeting
2019 ASCO Annual Meeting
Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy.
Authors
Khashayar Esfahani
Jewish General Hospital McGill University, Montreal, QC, Canada
Khashayar Esfahani , Pamela Thebault , Rejean Lapointe , Rahima Jamal , Wilson H. Miller Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT01676649
Citation
J Clin Oncol 37, 2019 (suppl; abstr 9561)
DOI
10.1200/JCO.2019.37.15_suppl.9561
Abstract #
9561
Poster Bd #
132
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A clinical insight into therapeutic sequence in advanced melanoma.
First Author: Jesus Vera Aguilera
Poster
2012 ASCO Annual Meeting
Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma.
First Author: Shigehisa Kitano
Poster
2023 ASCO Annual Meeting
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
First Author: Patrick M. Forde